In:
PLOS ONE, Public Library of Science (PLoS), Vol. 16, No. 7 ( 2021-7-22), p. e0254898-
Abstract:
Cefaclor, a second-generation oral cephalosporin, is the most frequently prescribed cephalosporin in Korea. Studies, however, have yet to analyze the incidence of cefaclor-associated adverse drug reactions (ADRs), including hypersensitivity (HS), according to total national usage rates. This study aimed to investigate the incidence rates and clinical features of cefaclor ADRs reported to the Korean Adverse Event Reporting System (KAERS) and Health Insurance Review and Assessment Service (HIRA) database for the most recent 5 years. Reviewing the HIRA database, which contains information on all insurance claims, including prescribed medications and patient demographics, we identified the total number of individuals who had been prescribed cefaclor and other cephalosporins including 2 nd generation without cefaclor and 3 rd generation antibiotics from January 2014 to December 2018. Additionally, we retrospectively analyzed all ADRs reported to the KAERS for these drugs over the same study period. Incidence rates for ADRs, HS, and anaphylaxis to cefaclor were 1.92/10,000 persons, 1.17/10,000 persons, and 0.38/10,000 persons, respectively, lower than those to other 2 nd and 3 rd cephalosporins. Among all ADRs, HS (60.9% vs. 43.6% vs. 44.8%, P 〈 0.001) and anaphylaxis (19.8% vs. 4.6% vs. 4.7%, P 〈 0.001) were more common for cefaclor than for other 2 nd and 3 rd cephalosporins. Females, individuals under 65 years of age, concomitant use of drugs, and serious ADRs were more strongly associated with HS to cefaclor than with HS to other 2 nd and 3 rd cephalosporins. In a nationwide database for the Korean population, the incidence of cefaclor-induced ADRs, particularly HS and anaphylaxis, was high. Female sex, age younger than 65 years, and concomitant use of drugs may be associated with HS to cefaclor.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0254898
DOI:
10.1371/journal.pone.0254898.g001
DOI:
10.1371/journal.pone.0254898.g002
DOI:
10.1371/journal.pone.0254898.t001
DOI:
10.1371/journal.pone.0254898.t002
DOI:
10.1371/journal.pone.0254898.t003
DOI:
10.1371/journal.pone.0254898.t004
DOI:
10.1371/journal.pone.0254898.t005
DOI:
10.1371/journal.pone.0254898.s001
DOI:
10.1371/journal.pone.0254898.s002
DOI:
10.1371/journal.pone.0254898.s003
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2021
detail.hit.zdb_id:
2267670-3
Permalink